Genmab — November 2016
-
Tror altså heller ikke der kommer noget decideret nyt frem under ASH i forhold til de andre år, som for alvor kan rykke kursen. tror det er salget fra nu af der rykker kursen lidt opad, men det er det nye der skal sparke røv og der går vel en rum tid endnu eller?
-
Nyt isatuximab studie (bl.a. til at undersøge patienter tidligere behandlet med dara) https://clinicaltrials.gov/ct2/show/NCT02514668?term=daratumumab&lup_s=11%2F20%2F2016&lup_e=11%2F28%2F2016&rank=1
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind